株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗血栓剤の世界市場 (2017〜2027年):抗凝固剤、血小板凝固阻止剤、繊維素溶解剤

Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelet, Fibrinolytics

発行 Visiongain Ltd 商品コード 262260
出版日 ページ情報 英文 185 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=155.00円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
抗血栓剤の世界市場 (2017〜2027年):抗凝固剤、血小板凝固阻止剤、繊維素溶解剤 Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelet, Fibrinolytics
出版日: 2017年07月12日 ページ情報: 英文 185 Pages
概要

世界の抗血栓剤市場の収益額は、2016年時点で180億8000万米ドル程度、また今後のCAGR (複合年間成長率) は7.9%と推計されています。そのうちの58.8%が抗凝固剤で占められています。

当レポートでは、世界の抗血栓剤市場について分析し、血液凝固の要因・メカニズムや、関連疾患の概要・治療法、全体的な市場構造と動向見通し、製品別・国別の詳細動向、現在の治験の進展状況、主な市場促進・抑制要因、主要企業のプロファイル、現在開発中のパイプライン製品、業界全体の求心力 (SWOT分析)、今後の市場成長の可能性などを調査・考察しております。

第1章 分析概要

第2章 血液凝固:メカニズム、疾患、現在の治療法

  • 鬱血と凝固の理解
  • 血栓症とは
  • 血栓症の合併症
  • 抗血栓剤による治療

第3章 抗血栓剤:世界市場

  • 世界の抗血栓剤市場:最新動向
  • 世界の抗血栓剤市場:全体的な売上高の予測 (通算12年間分)
  • 抗血栓剤市場の促進・抑制要因
    • 患者人口の増加による市場成長の促進
    • ジェネリック医薬品との競合激化による、市場の抑制
  • 抗血栓剤市場:治療クラス別の市場収益額・シェア予測
  • 抗血栓剤市場:治療クラス別の市場収益額の予測、グループ別 (通算12年間分)
  • 抗凝固剤市場:今後の主な動向の見通し
    • 第Xa因子の直接阻害剤
    • ヘパリン
    • トロンビン直接因子
    • ビタミンK拮抗剤
  • 血小板凝固阻止剤:第二の主な治療クラス
  • 繊維素溶解剤:今後も、抗血栓剤市場の中核となる

第4章 主要製品の市場動向見通し (今後11年間分)

  • XareltoとEliquis:ジェネリック医薬品との競合にも関わらず、市場の支配権を維持
  • 抗血栓剤市場の主要な医薬品:収益額・市場シェアの比較
  • 今後の市場成長率が最大となるのは、どの医薬品か?
  • Plavix
  • Lovenox
  • Xarelto
  • Pradaxa
  • Activase
  • Effien
  • Aspirin Cardio
  • Angiomax/Angiox
  • Pletal
  • Aggrenox/Asasantin
  • Fragmin
  • Brilinta/Brilique
  • Eliquis
  • Arixtra
  • 抗血栓剤市場での新薬認証
    • Zontivity
    • Lixiana/Savaysa

第5章 主要国市場 (通算12年間分)

  • 抗血栓剤の売上高が最上位となる国々:最新データ
  • 主要国の抗血栓剤市場:収益額・市場データの比較
  • 今後の市場成長率が最も大きな国々
  • 米国市場
  • 欧州主要5ヶ国 (EU5) 市場 (ドイツ・フランス・英国・イタリア・スペイン)
  • 日本市場
  • 中国市場
  • ブラジル市場
  • インド市場
  • ロシア市場

第6章 抗血栓剤の開発:研究開発 (R&D) パイプライン

  • 抗血栓剤のR&Dパイプライン:概要
  • 血小板凝固阻止剤のR&Dパイプライン
  • 抗凝血剤のR&Dパイプライン
  • 繊維素溶解剤のR&Dパイプライン
  • その他の抗血栓剤のR&Dパイプライン

第7章 抗血栓剤市場の主要企業

  • 世界の主要な抗血栓剤メーカー:現在・将来の動向見通し
  • Sanofi
  • Boehringer Ingelheim
  • Bayer
  • Johnson & Johnson
  • Genentech
  • The Medicines Company
  • Eli Lilly
  • 大塚製薬
  • Pfizer
  • Bristol-Myers Squibb

第8章 抗血栓剤市場の質的分析 (SWOT分析)

  • 市場の強みと弱み
  • 市場の機会と脅威
  • STEP分析:今後の社会的・技術的・経済的・政治的要因の分析

第9章 分析結果

  • 世界市場の動向予測 (今後11年間分)
  • 主要国市場の動向予測 (今後11年間分)
  • 今後の業界の主な動向

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0211

Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelets, Fibrinolytics

The revenue of the antithrombotic drugs market in 2016 is estimated at $18.08bn and is expected to grow at a CAGR of 7.9% in the first half of the forecast period. The anticoagulants segment accounted for the largest share of the market in 2016, this segment held 58.5% of the antithrombotic drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 185-page report you will receive 84 tables and 69 figures - all unavailable elsewhere.

The 185-page report provides clear detailed insight into the antithrombotic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Antithrombotic drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the main submarkets:
    • Anticoagulants
    • Antiplatelet agents
    • Fibrinolytic treatments
  • This report provides the revenue forecast for these anticoagulant agents:
    • Direct factor Xa inhibitors
    • Heparins
    • Direct thrombin inhibitors
    • Vitamin K antagonists
  • This report provides the revenue forecast for the leading products in this market:
    • Xarelto
    • Plavix
    • Lovenox
    • Eliquis
    • Pradaxa
    • Activase
    • Brilinta/Brilique
    • Aspirin Cardio
    • Effient
    • Aggrenox/Asasantin
    • Fragmin
    • Pletal
    • Angiomax/Angiox
    • Rest of Market
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Japan
    • China
    • Brazil
    • Russia
    • India
    • Rest of World

image1

  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
  • Our study includes SWOT and STEP analysis of the antithrombotic drugs market.
  • Our study discusses the selected leading companies that are the major players in the antithrombotic drugs market:
    • Bayer
    • Bristol Myers Squibb
    • Sanofi
    • Boehringer-Ingelheim
    • Roche (Genentech)
    • AstraZeneca
    • Eli Lilly
    • Pfizer
    • Otsuka Pharmaceutical
    • The Medicines Company

Visiongain's study is intended for anyone requiring commercial analyses for the antithrombotic drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Antithrombotic Drugs
  • 1.2 Why Should You Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain
  • 1.10 Glossary of Abbreviations

2. Blood Clotting: Mechanisms, Disorders and Current Treatments

  • 2.1 Understanding Haemostasis and Coagulation
  • 2.2 What is Thrombosis
  • 2.3 Complications of Thrombosis
    • 2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
    • 2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
    • 2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
  • 2.4 Antithrombotic Drug Treatment

3. Antithrombotic Drugs: World Market 2017-2027

  • 3.1 The World Antithrombotic Drug Market in 2015 and 2016
  • 3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2016-2027
  • 3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
    • 3.3.1 An Increasing Patient Population Drives Market Growth
    • 3.3.2 Intense Competition from Generics Threatens to Restrain the Market
  • 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
  • 3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2016-2027
  • 3.6 Anticoagulant Drugs: Leading the Market from 2016 Onwards
    • 3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class with Great Potential
    • 3.6.2 Heparins: The Second-Leading Anticoagulant Class in 2016
    • 3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2015 and 2016
    • 3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
  • 3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2016
  • 3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4. Leading Products in the Market: Prospects, 2017-2027

  • 4.1 Xarelto and Eliquis Remain the Market Leaders in 2016, Despite Generic Competition
  • 4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2022 and 2027
  • 4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2027?
  • 4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
    • 4.4.1 Branded Competition for Plavix?
  • 4.5 Lovenox: Biosimilar Competition in the EU is Expected
  • 4.6 Xarelto: Leading Antithrombotic of 2015
  • 4.7 Pradaxa's Continued Growth in 2016
  • 4.8 Activase Leads the Fibrinolytics Market, With Little Competition
  • 4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
  • 4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
  • 4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
  • 4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
  • 4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
  • 4.14 Fragmin Faces Rivalry from Generic Competition to Lovenox
  • 4.15 Brilinta/Brilique: Investigation Closed in 2014
  • 4.16 Eliquis: Will Late Entry to the Market Affect Uptake?
  • 4.17 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
  • 4.18 New Approvals in the Antithrombotic Drugs Market
    • 4.18.1 Zontivity: The Newest Approval In Antithrombotics
    • 4.18.2 Lixiana/Savaysa: Expansion into Other Regional Markets

5. Leading National Markets 2016-2027

  • 5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2015 and 2016?
  • 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2021 and 2027
  • 5.3 Which National Markets Will Grow Fastest to 2027?
  • 5.4 The US: Dominating the Antithrombotic Drug Market Through 2016-2027
  • 5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
    • 5.5.1 Germany Leads the EU5
    • 5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
    • 5.5.3 UK: Pharmaceutical Price Regulation Scheme
    • 5.5.4 Italy's Healthcare System - Advantages Conducive to Business
    • 5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
  • 5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2017-2027
  • 5.7 The Chinese Antithrombotic Drug Market Will Capture Market Share
  • 5.8 The Brazilian Antithrombotic Drug Market 2017-2027: Strong Growth as Universal Healthcare Coverage is Expanded
  • 5.9 The Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?
  • 5.10 The Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth

6. Antithrombotic Drug Development: R&D Pipeline

  • 6.1 The R&D Pipeline for Antithrombotic Drugs: Overview
  • 6.2 The Antiplatelet Drug R&D Pipeline in 2016
    • 6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
    • 6.2.2 The Medicines Company's Kangrexel (Cangrelor) Received Approval
  • 6.3 The R&D Pipeline for Anticoagulants, 2016
    • 6.3.1 Heparins: Little R&D Activity in 2016
    • 6.3.2 The Vitamin K Antagonist Pipeline
    • 6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
    • 6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
    • 6.3.5 Portola Pharmaceuticals' Betrixaban
    • 6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
  • 6.4 The Fibrinolytics R&D Pipeline, 2016
    • 6.4.1 Lundbeck's Desmoteplase: Failed to Meet Primary Endpoint in Phase III
    • 6.4.2 Bharat Biotech and ThromboGenics' THR-100
  • 6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2016
    • 6.5.1 Kyowa Hakko Kirin's KW-3357: Filed in Japan
    • 6.5.2 Asahi Kasei Pharma America's ART 123
    • 6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
    • 6.5.4 Isis Pharmaceuticals' ISIS-FXI Rx

7. Leading Companies in the Antithrombotic Drug Market

  • 7.1 Leading Antithrombotic Drug Manufacturers in 2015 and 2016
  • 7.2 Sanofi Leads the Market, but is its Position Under Threat?
  • 7.3 Boehringer Ingelheim Captures Market Share
  • 7.4 Bayer Markets Two Antithrombotic Drugs
  • 7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio
  • 7.6 Genentech Will Retain Market Share
  • 7.7 The Medicines Company's Position Will be Bolstered by the Launch of its New Drug
  • 7.8 Eli Lilly: Market Position is Dependent on Success of Effient
  • 7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
  • 7.10 Pfizer: A Gradually Increasing Share of the Market
  • 7.11 Bristol-Myers Squibb Expected to Lead the Market 2017 onwards

8. Qualitative Analysis of the Antithrombotic Drugs Market, 2016

  • 8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2016
    • 8.1.1 Thrombotic Disease: Management Rather Than Cure
    • 8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
  • 8.2 Opportunities and Threats Facing the Market 2016-2027
    • 8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
    • 8.2.2 Further Development of Existing Drugs
    • 8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
    • 8.2.4 The Threat of Generic Competition
    • 8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
    • 8.2.6 High Risk of Investment in New Drug Development
    • 8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
  • 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2017-2027
    • 8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
    • 8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
    • 8.3.3 Economic Factors
    • 8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?

9. Conclusions from Our Study

  • 9.1 The World Market for Antithrombotic Drugs 2017-2027
    • 9.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
  • 9.2 The Leading National Markets 2017-2027
  • 9.3 Trends in the Industry
    • 9.3.1 The Market Will Recover From Plavix Decline
    • 9.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
    • 9.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
    • 9.3.4 High Barriers to Market Entry and a Limited Pipeline - The Implications

Appendices

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016
  • Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
  • Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2015 and 2016
  • Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.3 The Antithrombotic Drug Market by Therapeutic
  • Class: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027
  • Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027
  • Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027
  • Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.9 The Warfarin Market: Companies and Year of Introduction
  • Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016
  • Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
  • Table 4.4 Plavix: Key Facts, 2016
  • Table 4.5 Selected Generic Competitors Approved by the FDA, 2016
  • Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.7 Lovenox: Key Facts, 2016
  • Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.9 Xarelto: Key Facts, 2016
  • Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.11 Pradaxa: Key Facts, 2014
  • Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.13 Activase: Key Facts, 2016
  • Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.15 Effient: Key Facts, 2016
  • Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.17 Aspirin Cardio: Key Facts, 2016
  • Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.19 Angiomax/Angiox: Key Facts, 2016
  • Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.21 Pletal: Key Facts, 2016
  • Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.23 Aggrenox/Asasantin: Key Facts, 2016
  • Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.25 Fragmin: Key Facts, 2016
  • Table 4.26 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.27 Brilinta: Key Facts, 2016
  • Table 4.28 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.29 Eliquis: Key Facts, 2016
  • Table 4.30 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 4.31 Arixtra: Key Facts, 2016
  • Table 4.32 Zontivity: Key Facts, 2016
  • Table 4.33 Lixiana/Savaysa: Key Facts, 2016
  • Table 5.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016
  • Table 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027
  • Table 5.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
  • Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027
  • Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
  • Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2016
  • Table 6.2 Selected Candidates in the Heparins Pipeline, 2016
  • Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014
  • Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2016
  • Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2016
  • Table 6.6 The Fibrinolytics R&D Pipeline, 2016
  • Table 6.7 Other Antithrombotic Drugs in Development, 2016
  • Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2015 and 2016
  • Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2016
  • Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2016
  • Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2016
  • Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2016
  • Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2016
  • Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2016
  • Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2016
  • Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2016
  • Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2016
  • Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2016
  • Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2016
  • Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2016-2027
  • Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2017-2027

List of Figures

  • Figure 2.1 Diagram Depicting the Coagulation Cascade
  • Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2015
  • Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Share (%), 2016
  • Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2016-2027
  • Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2021
  • Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2027
  • Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2016-2027
  • Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027
  • Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2016-2027
  • Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2017-2027
  • Figure 3.11 Heparins: Revenue Forecast ($m), 2016-2027
  • Figure 3.12 The Heparins Market: Drivers and Restraints, 2017-2027
  • Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2016-2027
  • Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2017-2027
  • Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2016-2027
  • Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2016-2027
  • Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2016-2027
  • Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2017-2027
  • Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2016-2027
  • Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2017-2027
  • Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2015
  • Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2016
  • Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2022
  • Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2027
  • Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
  • Figure 4.6 Plavix: Revenue Forecast ($m), 2016-2027
  • Figure 4.7 Lovenox: Revenue Forecast ($m), 2016-2027
  • Figure 4.8 Xarelto: Revenue Forecast ($m), 2016-2027
  • Figure 4.9 Pradaxa: Revenue Forecast ($m), 2016-2027
  • Figure 4.10 Activase: Revenue Forecast ($m), 2016-2027
  • Figure 4.11 Effient: Revenue Forecast ($m), 2016-2027
  • Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2016-2027
  • Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2016-2027
  • Figure 4.14 Pletal: Revenue Forecast ($m), 2016-2027
  • Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2016-2027
  • Figure 4.16 Fragmin: Revenue Forecast ($m), 2016-2027
  • Figure 4.17 Brilinta: Revenue Forecast ($m), 2016-2027
  • Figure 4.18 Eliquis: Revenue Forecast ($m), 2014-2025
  • Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2015
  • Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2016
  • Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2021
  • Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2027
  • Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
  • Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2016-2027
  • Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
  • Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2016-2027
  • Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
  • Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2016
  • Figure 7.1 The Top 10 Companies: Market Shares (%), 2015
  • Figure 7.2 The Top 10 Companies: Market Shares (%), 2016
  • Figure 9.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2015-2027
  • Figure 9.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2016, 2021 and 2027

Companies Listed

  • Abbott Laboratories
  • Ablynx
  • Aché
  • Accord Healthcare
  • Actavis Totowa
  • AdvanceCor GmbH
  • Alchemia
  • Amneal Pharms
  • Amphastar Pharmaceuticals
  • Apotex
  • App Pharmaceuticals
  • ARCA biopharma
  • Armetheon
  • ARYx Therapeutics
  • Asahi Kasei Pharma America
  • Aspen
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Laboratories (subsidiary of Barr Pharmaceuticals)
  • Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
  • Bayer
  • Bharat Biotech
  • BioVascular
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Capital TEN II
  • Canyon Pharmaceuticals
  • CSL Behring
  • Daiichi Sankyo
  • Dexa Medica
  • Diakron Pharmaceuticals
  • Dr. Reddy's Laboratories
  • DuPont Merck
  • Eisai
  • Eli Lilly
  • EMS
  • Endo Laboratories
  • ESP Pharma
  • Eurofarma
  • Fournier Pharma
  • Gate Pharmaceuticals
  • Genentech
  • GlaxoSmithKline (GSK)
  • Grifols Therapeutics
  • Hercules Bioventures Partners
  • Hoechst Marion Roussell
  • Hospira
  • Hypermarcas
  • Invagen Pharms
  • IPCA Labs
  • Isis Pharmaceuticals
  • Johns Hopkins Medicine
  • Johnson & Johnson (J&J)
  • Kowa
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical
  • LG Life Sciences
  • LIMES Institute
  • Lundbeck
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Mitsubishi
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mutual Pharmaceuticals
  • Mylan Pharmaceuticals
  • Novartis
  • Nuvelo
  • Organon
  • Otsuka Pharmaceutical Company
  • Pfizer
  • Pharmacia
  • PLIVA
  • PLx Pharma
  • Portola Pharmaceuticals
  • Pozen
  • Regado Biosciences
  • Roche
  • Roxane Laboratories
  • Sandoz
  • Sanofi
  • ScieGen Pharmaceuticals
  • Sun Pharmaceuticals Indusdtries
  • Takeda
  • Taro
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • ThromboGenics
  • Tianjin Medical
  • Tobira Therapeutics
  • Torrent Pharmaceuticals
  • Tufts Medical Center
  • Upjohn AB
  • USL Pharma
  • Wockhardt
  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
  • Zydus Cadila
  • Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)

Organizations Mentioned in the Report

  • Baylor College of Medicine, Houston, Texas
  • Committee on Medicinal Products for Human Use (CHMP)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • Indonesia University
  • Judicial Panel on Multidistrict Litigation (US)
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • Unified Health System (SUS)
  • Universidade Federal de São Paulo
  • University General Hospital
  • University of Insubria (Italy)
  • US Department of Justice
  • Virginia Commonwealth University
  • World Health Organization (WHO)
Back to Top